Good OS with chemoimmunotherapy in Japan lung cancer study

  • Kimura H & al.
  • Cancer Immunol Immunother
  • 31 May 2018

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with lung cancer who received adjuvant chemotherapy plus immunotherapy (chemoimmunotherapy) after surgical resection had significantly better OS and recurrence-free survival (RFS) than patients who had adjuvant chemotherapy alone after surgery.

Why this matters

  • Patients aged ≤55 years, men, and those with adenocarcinoma or stage III tumors are good candidates for immunotherapy.

Study design

  • Randomized, phase 3 study.
  • 101 patients with resected lung cancer received chemoimmunotherapy (group A; n=50) or adjuvant chemotherapy (group B; n=51).
  • Median follow-up, 59.6 months.
  • Immunotherapy consisted of the adoptive transfer of autologous activated cytotoxic killer T cells and dendritic cells.
  • Funding: None.

Key results

  • OS significantly higher (HR, 0.439; 95% CI, 0.239-0.807) in group A vs group B (2-, 5-, and 7-year OS 96.0%, 69.4%, and 55.1% in group A vs 64.7%, 45.1%, and 38.1% in group B, respectively).
  • RFS also significantly higher (HR, 0.473; 95% CI, 0.275-0.812) in group A vs group B (2-, 5-, and 7-year RFS 70.0%, 57.9%, and 47.5% in group A vs 43.1%, 31.4%, and 28.5% in group B, respectively).
  • Subgroup analyses found that patients aged ≤55 years, men, and those with adenocarcinoma or stage III tumors had better OS and RFS with immunotherapy.

Limitations

  • Single-center study with small cohort.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit